Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission (EC) has granted Marketing Authorization for Yescarta® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. The Marketing Authorization approves axicabtagene ciloleucel for use in the 28 countries of the European Union, Norway, Iceland and Liechtenstein.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180827005248/en/
Axicabtagene ciloleucel is a chimeric antigen receptor T cell (CAR T) therapy, which harnesses a patient’s own immune system to fight certain types of blood cancer. The cell therapy has been proven to induce complete response (no detectable cancer) in a proportion of patients with relapsed or refractory DLBCL and PMBCL, which are aggressive forms of non-Hodgkin lymphoma (NHL).
“Axicabtagene ciloleucel is a new and exciting way of treating cancer that offers a new option to patients with DLBCL and PMBCL in Europe,” said Professor Gilles Salles, Head of Hematology, South Lyon Hospital Complex. “Many patients with these aggressive forms of non-Hodgkin lymphoma who have not responded to or failed commonly available treatment options have a very poor prognosis and there is an urgent need for new therapies.”
The Marketing Authorization Application (MAA) is supported by data from the ZUMA-1 trial of axicabtagene ciloleucel in adult patients with refractory aggressive NHL. In the single-arm trial, 72 percent of patients (n=73/101) who received a single infusion of axicabtagene ciloleucel responded to therapy, with 51 percent (n=52/101) achieving a complete response (as assessed by an independent review committee, median follow-up of 15.1 months). At one year following infusion, 60 percent of patients were alive (95% CI: 50.2, 69.2) and the median overall survival (OS) had not been reached (95% CI: not estimable [NE]).
Axicabtagene ciloleucel may cause side effects that are severe or life threatening, such as cytokine release syndrome (CRS) or neurological toxicities. In ZUMA-1, 12 percent of patients experienced Grade 3 or higher CRS and 31 percent experienced Grade 3 or higher neurologic toxicities. Overall 98 percent of patients recovered from CRS and/or neurologic adverse reactions. Treatment algorithms have been developed to manage some of the symptoms associated with both CRS and neurologic adverse reactions experienced by patients on axicabtagene ciloleucel.
The most common Grade 3 or higher adverse reactions include encephalopathy, unspecified pathogen infection, CRS, bacterial infection, aphasia, viral infection, delirium, hypotension and hypertension.
For full details on the Special Warnings and Precautions for Use and Adverse Reactions (including appropriate management) please refer to the EU Summary of Product Characteristics (SmPC).
“We are proud to be leading this frontier of cancer innovation that is bringing novel, personalized therapy to people living with these blood cancers,” said Alessandro Riva, MD, Gilead's Executive Vice President, Oncology Therapeutics & Head, Cell Therapy. “Our vision is for cell therapy to serve as the foundation for treating all cancer types. Today’s milestone is another step on this exciting and important journey.”
Axicabtagene ciloleucel was approved by the U.S. Food and Drug Administration on October 18, 2017.
Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that physicians may not see the benefits of prescribing axicabtagene ciloleucel for the treatment of DLBCL and PMBCL and the possibility of unfavorable results from additional clinical trials involving axicabtagene ciloleucel. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation to update any such forward-looking statements.
Full European Summary of Product Characteristics for Yescarta ® is available from the EMA website at www.ema.europa.eu .
Yescarta is a registered trademark of Gilead Sciences, Inc., or its related companies.
For more information on Kite, please visit the company’s website at www.kitepharma.com . Learn more about Gilead at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Gilead Sciences, Inc.
Sung Lee, +1-650-524-7792
Nathan Kaiser, +1-650-522-1853
Sarah Swift, +44 (208) 587-2618
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rocket Software to Acquire OpenText’s Application Modernization and Connectivity Business28.11.2023 22:20:00 CET | Press release
Rocket Software, Inc. (“Rocket Software”), a global technology leader driving modernization for the world’s largest companies, today announced it has signed a definitive agreement to acquire the Application Modernization and Connectivity business (AMC) of OpenText (NASDAQ: OTEX), (TSX: OTEX), which was formerly part of Micro Focus. The total purchase price is $2.275B. For decades, Rocket Software has been the partner solving complex IT challenges for the largest and most innovative organizations, across infrastructure, data, and applications. Rocket Software’s hybrid cloud strategy empowers customers to optimize their application portfolio wherever they are in their modernization journey, enabling them to bridge the gap to modern use cases without disrupting their mission-critical operations. This approach allows organizations to benefit from the mainframe's security and dependability while also taking advantage of powerful analytics tools in the cloud. AMC has been a leader in applica
NetApp and AWS Deliver a Nine Times Performance Increase for Amazon FSx for NetApp ONTAP28.11.2023 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, announced at re:Invent, scale-out FSx for ONTAP® file systems through its collaboration with AWS. Scale-out file systems offer up to nine times higher storage performance compared to existing file systems, enabling customers to run high-performance applications on AWS more quickly and efficiently. FSx for ONTAP enables customers to use ONTAP’s data management features for a wide variety of workloads, such as user and application file shares, relational databases (SAP HANA), data stores for VMware cloud on AWS and backup and disaster recovery. With the new enhancements, customers can now use FSx for ONTAP for a broader range of higher-performance use cases, such as high-performance computing (HPC), electronic design automation (EDA), visual effects (VFX) and film editing, life sciences, seismic analysis, machine learning, and generative AI. Organizations of all sizes are migrating on-premises workloads to AWS or deploy
Varberg Energi Selects Hansen to Power Intraday Trading28.11.2023 20:50:00 CET | Press release
Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, water and communications industries, is pleased to announce Varberg Energi, a Swedish energy company, as a new Hansen customer. Varberg Energi, which has recently added physical-trading operations and balance responsibility to its services, will leverage Hansen Trade to enable this. The intraday trading solution within Hansen Trade will allow Varberg Energi to automate intraday trading operations and balance management. With Hansen Trade as part of its everyday operating infrastructure, Varberg Energi will be able to take advantage of physical trading operations without the need to spend significant time and effort on manual operations. Jens Nordberg, Head of Energy Trading, Varberg Energi, commented: “We have recently made a strategic decision to insource physical-trading operations and balance responsibility. Combined with our flexibility portfolio, we believe that this will create the ri
Abu Dhabi’s Advanced Technology Research Council launches ‘AI71’: New AI Company Pioneering Decentralised Data Control for Companies & Countries28.11.2023 18:16:00 CET | Press release
In an era of rapid advancements across artificial intelligence (AI), Abu Dhabi’s Advanced Technology Research Council (ATRC) is making yet another bold stride with the launch of its new AI company, AI71. The entity builds on the Technology Innovation Institute’s (TII) Falcon generative AI models and will focus on multi-domain specializations while offering unprecedented AI data control options for companies and countries looking to self-host for greater privacy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128549220/en/ H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council launches AI71 along with H.E Faisal Al Bannai, Secretary General, Advanced Technology Research Council (Photo: AETOSWire) The new AI powerhouse was launched by H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Cou
Pixitmedia Amplifies Presence in US Market via Distribution and Reseller Agreement with JB&A28.11.2023 17:55:00 CET | Press release
pixitmedia, a Kalray company (Euronext Growth Paris: ALKAL) and a global leader in software-defined storage and data management and orchestration solutions for the media and entertainment industry, today announces expansion into the U.S. market by naming JB&A as its primary distribution partner. JB&A is a leading distributor of technology products and solutions serving a wide range of industries including broadcast, post-production, live events, and more. JB&A is a subsidiary of DCC, a leading international sales, marketing, and support services group worldwide. This strategic alliance translates into significant growth opportunities in the North America market for pixitmedia, whose solutions integrate with media and entertainment workflows to drive data management and storage efficiency both on premises and in the cloud. This partnership also sets the stage to speed deployment of both pixitmedia and Kalray solutions into the US market. US-based media and entertainment customers can no